P1.116. Comparison Between Nivolumab + Ipilimumab, FOLFOX, and Nivolumab + FOLFOX Therapy as First-Line Therapy for Cisplatin-Unfit Advanced Esophageal Squamous Cell Carcinoma

Clicks: 19
ID: 325905
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #235 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Non-Surgical Treatment of Esophageal Cancer Background Nivolumab plus platinum-based chemotherapy and nivolumab plus ipilimumab (Nivo+Ipi) therapy are standard first-line treatments for advanced esophageal squamous cell carcinoma (ESCC). However, patients with renal or cardiac dysfunction and elderly patients might be unfit for cisplatin-containing regimens. Therefore, leucovorin, 5-FU, and oxaliplatin (FOLFOX), Nivo+Ipi, and nivolumab plus FOLFOX (Nivo+FOLFOX) therapy might be alternative options for cisplatin-unfit population. Methods This retrospective study included cisplatin-unfit patients with histologically confirmed advanced ESCC treated with Nivo+Ipi, FOLFOX, or Nivo+FOLFOX in our hospital from March 2021 to July 2025 for the first-line treatment. Effectiveness was evaluated by objective response rate (ORR) assessed by the RECIST ver.1.1, progression-free survival (PFS), and overall survival (OS). To evaluate safety, adverse events were assessed by CTCAE ver. 5.0. Results Fifty patients were included (median age, 75 years; performance status 0/1/≥2, 20/70/10%). Eighteen (36%), 18 (36%), and 14 (28%) patients received Nivo+Ipi, FOLFOX, and Nivo+FOLFOX therapy, respectively. Median follow-up time was 12.4 months. PFS was significantly longer with Nivo+Ipi than with FOLFOX (median 8.5 vs. 3.2 months; HR 0.40, 95% CI 0.17–0.93, p = 0.028), whereas there was no significant difference in OS (median NR vs. 13.3 months; HR 0.48, 95% CI 0.18–1.27, p = 0.13). Nivo+FOLFOX showed significant improvements in PFS (median 6.5 vs. 3.2 months; HR 0.42 95% CI 0.18–0.99, p = 0.041) and ORR (64% vs. 28%, p = 0.039) compared with FOLFOX. The most common any grade adverse events were rash in Nivo+Ipi (n = 3, 17%) and neutropenia in FOLFOX (n = 5, 28%) and Nivo+FOLFOX (n = 6, 43%). Conclusion Nivo+Ipi and Nivo+FOLFOX may show improved effectiveness compared with FOLFOX alone and appear to be generally well-tolerated in patients with cisplatin-unfit advanced ESCC.
Reference Key
openalex_W7204000845 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nozomu Ogura, Shun Yamamoto, Ryuichi Morita, Hiroshi Imazeki, Hideaki Takahashi, Yoshitaka Honma, Daisuke Kurita, Koshiro Ishiyama, Hiroyuki Daiko, Yasuyuki Seto, Ken Kato
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.264
URL
https://doi.org/10.1093/dote/doag077.264
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.